A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and AP1903 Infusion For Children With Recurrent or MRD Hematologic Malignancies After Allogeneic Transplant
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Rimiducid (Primary) ; Rivogenlecleucel (Primary)
- Indications Haematological malignancies; Leukaemia; Lymphoma; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bellicum Pharmaceuticals
- 24 Oct 2019 Planned End Date changed from 1 Mar 2033 to 1 Mar 2035.
- 31 Aug 2018 Biomarkers information updated
- 13 Mar 2018 According to a Bellicum Pharmaceuticals medioa release, first patient has been dosed.